Nutraceuticals CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Dosage Form (Tablets & Capsules, Powder, Softgel, Others), By Service (Product Formulation and Development, Manufacturing and Packaging, Research & Development (R&D), Regulatory Compliance, Others), By Company Size (Small Companies, Mid-Sized Companies, Large Companies), By Region, and Competition, 2020-2030F

Market Overview

The Global Nutraceuticals CDMO Market, valued at USD 35.10 Billion in 2024, is projected to experience a CAGR of 7.90% to reach USD 55.39 Billion by 2030. Nutraceuticals are products derived from food sources that provide health benefits beyond basic nutrition, encompassing dietary supplements and functional foods. The global nutraceuticals Contract Development and Manufacturing Organization (CDMO) market experiences robust growth, primarily driven by increasing consumer awareness of preventative healthcare, an aging global population, and the escalating demand for specialized formulations and complex product development. For instance, according to the European Federation of Associations of Health Product Manufacturers, the European supplements sector was valued at approximately €18 billion in 2023, reflecting significant market activity. This sustained demand necessitates outsourcing specialized manufacturing and development capabilities, propelling the CDMO segment.

The expansion of the nutraceuticals market is further evidenced by consumer behavior. According to the Council for Responsible Nutrition, in 2024, 75% of Americans continued to use dietary supplements, with magnesium usage rising from 19% in 2023 to 23% of all supplement users. The median monthly expenditure for supplement users also increased slightly from $48 in 2023 to $50 in 2024. However, a significant challenge impeding market expansion is the navigation of a stringent and constantly evolving global regulatory landscape, demanding continuous adaptation and investment from CDMOs.

Key Market Drivers

The global nutraceutical CDMO market is experiencing substantial expansion, primarily driven by the escalating consumer demand for health and wellness products, alongside an increasing trend of outsourcing manufacturing and development within the nutraceutical sector. Consumers are proactively seeking dietary solutions that offer benefits beyond basic nutrition, a behavior pattern reflected in specific market segments. For instance, according to the International Probiotics Association, in March 2024, the Asia Pacific region contributed USD 3.7 billion to global probiotic supplement sales in 2023, representing 42% of the total. This sustained demand for diverse and specialized nutraceuticals necessitates advanced manufacturing capabilities and formulation expertise many brands often lack internally.

This growing need directly fuels the inclination among nutraceutical companies to outsource their manufacturing and development processes to specialized CDMOs. Such partnerships provide access to cutting-edge technology, regulatory compliance knowledge, and scalable production capacities, mitigating the significant capital investment of in-house facilities. A tangible demonstration of this trend is seen in strategic investments by CDMOs; according to Evonik Industries AG, in March 2023, the company established a new GMP facility to manufacture lipids for advanced pharmaceutical drug delivery applications, directly serving nutraceutical contract manufacturing needs. The overall confidence in this outsourcing model is further illustrated by substantial market activity, such as the $16.5-billion acquisition of the CDMO, Catalent, by Novo Holdings, the parent company of Novo Nordisk, as reported by PharmaLinkage in June 2024. These factors collectively underscore the dynamic growth trajectory of the nutraceutical CDMO market.

Download Free Sample Report

Key Market Challenges

A significant challenge impeding the expansion of the Global Nutraceuticals CDMO Market is the stringent and constantly evolving global regulatory landscape. The necessity for CDMOs to continuously adapt and invest in compliance measures directly hampers market growth by increasing operational complexities and costs. This dynamic environment requires substantial resource allocation for staying abreast of diverse national and international regulations, including ingredient approvals, labeling requirements, and manufacturing standards.

Such continuous investment in regulatory expertise, quality systems, and facility upgrades to meet new guidelines leads to higher overheads, impacting pricing strategies and potentially reducing the competitiveness of CDMOs. For instance, according to the National Association of Manufacturers, in 2022, the average U. S. manufacturer paid over $29,000 per employee per year to comply with federal regulations, calculated in 2023 dollars. This financial burden elevates the barrier to entry for new CDMOs and poses an ongoing strain on existing players, thereby limiting overall market expansion as resources are diverted from innovation or capacity building towards compliance.

Key Market Trends

The increasing consumer demand for tailored health solutions is significantly driving the market through personalized nutrition and custom formulation capabilities. Nutraceutical CDMOs are adapting their development and manufacturing processes to produce bespoke products that cater to individual health profiles, genetic predispositions, and lifestyle choices. This shift necessitates flexible production lines, advanced ingredient sourcing, and expertise in diverse formulations to meet evolving consumer expectations for unique dietary support. According to the Council for Responsible Nutrition's 2024 Consumer Survey, released in October 2024, 69% of supplement users emphasize the importance of a personalized regimen when selecting their products. This trend allows CDMOs to offer specialized services, from concept to commercialization, including small-batch production and complex ingredient integration.

The adoption of advanced technologies and AI in manufacturing represents another pivotal trend influencing the global nutraceutical CDMO market. CDMOs are investing in automation, artificial intelligence, and data analytics to enhance operational efficiency, ensure stringent quality control, and accelerate product innovation cycles. These technologies facilitate precise ingredient handling, optimize formulation processes, and enable predictive maintenance for equipment, reducing downtime and improving overall throughput. Augury's "State of Production Health" report in July 2024 indicated that 83% of industrial leaders were increasing their investment in AI for 2024, up from 63% in the prior year. Such technological integration allows CDMOs to manage complex projects with greater accuracy and speed, providing competitive advantages in a demanding market landscape.

Segmental Insights

The Tablets & capsule segment is a significant growth driver in the Global Nutraceuticals CDMO Market due to compelling consumer preferences and inherent manufacturing benefits. Consumers favor these dosage forms for their established convenience, ease of administration, and familiarity, which simplifies daily supplement routines. From a production standpoint, capsules offer substantial formulation flexibility, allowing for the encapsulation of various active ingredients with minimal excipients and providing diverse dosing possibilities. This adaptability further supports product differentiation through customizable appearances. Moreover, the robust regulatory frameworks, such as those managed by the Food and Drug Administration (FDA) for dietary supplements in the United States, ensure the consistent quality and safety of these widely accepted formats, thereby enhancing market confidence and demand.

Regional Insights

North America dominates the global nutraceuticals CDMO market, largely attributed to its well-established nutraceuticals industry and high consumer awareness regarding health and wellness, which fuels substantial demand for dietary supplements and functional foods. A robust regulatory framework, notably enforced by the Food and Drug Administration (FDA) in the United States and Health Canada, ensures stringent product safety and quality standards, cultivating strong consumer confidence. This is further supported by advanced manufacturing capabilities, significant research and development investments, and a prevalent focus on preventive healthcare across the region, solidifying North America's leading position in nutraceutical contract development and manufacturing.

Recent Developments

• In October 2025, Codis officially launched as a new global Contract Development and Manufacturing Organization (CDMO) specializing in commercial spray drying, amorphous solid dispersions, and particle engineering for the pharmaceutical, consumer health, and nutraceutical sectors. Formed by integrating Particle Dynamics in the US and EUROAPI's Haverhill, UK spray drying facility, Codis combines regulatory expertise and manufacturing strength. The new entity offers one of the largest commercial spray drying capacities globally, with facilities across the US and UK. This collaboration aimed to accelerate therapies from development to market for its global partners.

• In March 2025, Sirio, a specialist in gummies and softgels within the nutraceutical CDMO market, introduced its innovative XtraGummies technology. This new offering was developed to enhance the potency, sensory experience, and convenience of nutraceutical gummies. The technology allows for the incorporation of challenging functional ingredients, such as omega-3, creatine, and iron, into high-strength gummies with improved flavor profiles. Sirio stated that this breakthrough ensures that supplements are both nutritionally impactful and delivered in minimal doses, directly responding to the increasing global demand for high-strength, consumer-friendly nutraceutical products.

• In January 2025, Sirio Pharma, a prominent nutraceutical Contract Development and Manufacturing Organization (CDMO), announced its intention to construct a new production facility in Chonburi, Thailand. This strategic investment, approved for up to $40 million, marked Sirio's first manufacturing plant in Asia outside of China. The new site is designed to include gummy production capabilities and automatic packaging lines for various nutraceutical dose forms. This expansion aimed to address the growing demand in Southeast Asia, providing local resources to support international customers in this rapidly expanding region and enhancing Sirio's global manufacturing flexibility.

• In January 2024, NutraResearch, a company recognized for its innovation in nutraceuticals, prepared to launch a new array of advanced solutions. These developments were based on the company's controlled release platforms, designed to optimize the interaction of active ingredients within the body for more effective and specific actions. Notably, research focused on mucosal bioadhesion technology to enhance the efficacy of liquid supplements. This initiative enabled NutraResearch to broaden its offerings, covering both solid and liquid formats, and ensured that active components in dietary supplements would act precisely where and when needed, improving bioavailability.

Key Market Players

• Catalent Inc.
• Lonza Group AG
• NUTRASCIENCE LABS Inc
• Robinson Pharma, Inc.
• Health Wright Products, Inc.
• Innovations in Nutrition + Wellness
• INPHARMA S.p.A.
• Aenova Group
• NutraPak USA
• SFI Health Pty Ltd.

Report Scope:

In this report, the Global Nutraceuticals CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Nutraceuticals CDMO Market, By Dosage Form:

o   Tablets & Capsules

o   Powder

o   Softgel

o   Others

• Nutraceuticals CDMO Market, By Service:

o   Product Formulation and Development

o   Manufacturing and Packaging

o   Research & Development (R&D)

o   Regulatory Compliance

o   Others

• Nutraceuticals CDMO Market, By Company Size:

o   Small Companies

o   Mid-Sized Companies

o   Large Companies

• Nutraceuticals CDMO Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nutraceuticals CDMO Market.

Available Customizations:

Global Nutraceuticals CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Nutraceuticals CDMO Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]